241 related articles for article (PubMed ID: 25210493)
1. KRAS and DAXX/ATRX gene mutations are correlated with the clinicopathological features, advanced diseases, and poor prognosis in Chinese patients with pancreatic neuroendocrine tumors.
Yuan F; Shi M; Ji J; Shi H; Zhou C; Yu Y; Liu B; Zhu Z; Zhang J
Int J Biol Sci; 2014; 10(9):957-65. PubMed ID: 25210493
[TBL] [Abstract][Full Text] [Related]
2. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors.
Jiao Y; Shi C; Edil BH; de Wilde RF; Klimstra DS; Maitra A; Schulick RD; Tang LH; Wolfgang CL; Choti MA; Velculescu VE; Diaz LA; Vogelstein B; Kinzler KW; Hruban RH; Papadopoulos N
Science; 2011 Mar; 331(6021):1199-203. PubMed ID: 21252315
[TBL] [Abstract][Full Text] [Related]
3. Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors.
Marinoni I; Kurrer AS; Vassella E; Dettmer M; Rudolph T; Banz V; Hunger F; Pasquinelli S; Speel EJ; Perren A
Gastroenterology; 2014 Feb; 146(2):453-60.e5. PubMed ID: 24148618
[TBL] [Abstract][Full Text] [Related]
4. Alternative lengthening of telomeres and ATRX/DAXX loss can be reliably detected in FNAs of pancreatic neuroendocrine tumors.
VandenBussche CJ; Allison DB; Graham MK; Charu V; Lennon AM; Wolfgang CL; Hruban RH; Heaphy CM
Cancer Cytopathol; 2017 Jul; 125(7):544-551. PubMed ID: 28371511
[TBL] [Abstract][Full Text] [Related]
5. Genes involved in angiogenesis and mTOR pathways are frequently mutated in Asian patients with pancreatic neuroendocrine tumors.
Chou WC; Lin PH; Yeh YC; Shyr YM; Fang WL; Wang SE; Liu CY; Chang PM; Chen MH; Hung YP; Li CP; Chao Y; Chen MH
Int J Biol Sci; 2016; 12(12):1523-1532. PubMed ID: 27994516
[No Abstract] [Full Text] [Related]
6. DAXX/ATRX and MEN1 genes are strong prognostic markers in pancreatic neuroendocrine tumors.
Park JK; Paik WH; Lee K; Ryu JK; Lee SH; Kim YT
Oncotarget; 2017 Jul; 8(30):49796-49806. PubMed ID: 28591701
[TBL] [Abstract][Full Text] [Related]
7. Altered telomeres in tumors with ATRX and DAXX mutations.
Heaphy CM; de Wilde RF; Jiao Y; Klein AP; Edil BH; Shi C; Bettegowda C; Rodriguez FJ; Eberhart CG; Hebbar S; Offerhaus GJ; McLendon R; Rasheed BA; He Y; Yan H; Bigner DD; Oba-Shinjo SM; Marie SK; Riggins GJ; Kinzler KW; Vogelstein B; Hruban RH; Maitra A; Papadopoulos N; Meeker AK
Science; 2011 Jul; 333(6041):425. PubMed ID: 21719641
[TBL] [Abstract][Full Text] [Related]
8. Loss of ATRX or DAXX expression and concomitant acquisition of the alternative lengthening of telomeres phenotype are late events in a small subset of MEN-1 syndrome pancreatic neuroendocrine tumors.
de Wilde RF; Heaphy CM; Maitra A; Meeker AK; Edil BH; Wolfgang CL; Ellison TA; Schulick RD; Molenaar IQ; Valk GD; Vriens MR; Borel Rinkes IH; Offerhaus GJ; Hruban RH; Matsukuma KE
Mod Pathol; 2012 Jul; 25(7):1033-9. PubMed ID: 22575867
[TBL] [Abstract][Full Text] [Related]
9. Alternative Lengthening of Telomeres and Loss of DAXX/ATRX Expression Predicts Metastatic Disease and Poor Survival in Patients with Pancreatic Neuroendocrine Tumors.
Singhi AD; Liu TC; Roncaioli JL; Cao D; Zeh HJ; Zureikat AH; Tsung A; Marsh JW; Lee KK; Hogg ME; Bahary N; Brand RE; McGrath KM; Slivka A; Cressman KL; Fuhrer K; O'Sullivan RJ
Clin Cancer Res; 2017 Jan; 23(2):600-609. PubMed ID: 27407094
[TBL] [Abstract][Full Text] [Related]
10. Context matters - Daxx and Atrx are not robust tumor suppressors in the murine endocrine pancreas.
Sun C; Estrella JS; Whitley EM; Chau GP; Lozano G; Wasylishen AR
Dis Model Mech; 2022 Aug; 15(8):. PubMed ID: 35976056
[TBL] [Abstract][Full Text] [Related]
11. Hotspot DAXX, PTCH2 and CYFIP2 mutations in pancreatic neuroendocrine neoplasms.
Vandamme T; Beyens M; Boons G; Schepers A; Kamp K; Biermann K; Pauwels P; De Herder WW; Hofland LJ; Peeters M; Van Camp G; Op de Beeck K
Endocr Relat Cancer; 2019 Jan; 26(1):1-12. PubMed ID: 30021865
[TBL] [Abstract][Full Text] [Related]
12. Altered PTEN, ATRX, CHGA, CHGB, and TP53 expression are associated with aggressive VHL-associated pancreatic neuroendocrine tumors.
Weisbrod AB; Zhang L; Jain M; Barak S; Quezado MM; Kebebew E
Horm Cancer; 2013 Jun; 4(3):165-75. PubMed ID: 23361940
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Significance of Altered ATRX/DAXX Gene in Pancreatic Neuroendocrine Tumors: A Meta-Analysis.
Wang F; Xu X; Ye Z; Qin Y; Yu X; Ji S
Front Endocrinol (Lausanne); 2021; 12():691557. PubMed ID: 34220718
[TBL] [Abstract][Full Text] [Related]
14. DAXX, ATRX, and MSI in PanNET and Their Metastases: Correlation with Histopathological Data and Prognosis.
Gisder DM; Overheu O; Keller J; Nöpel-Dünnebacke S; Uhl W; Reinacher-Schick A; Tannapfel A; Tischoff I
Pathobiology; 2023; 90(2):71-80. PubMed ID: 35691289
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic dysregulation and poorer prognosis in DAXX-deficient pancreatic neuroendocrine tumours.
Pipinikas CP; Dibra H; Karpathakis A; Feber A; Novelli M; Oukrif D; Fusai G; Valente R; Caplin M; Meyer T; Teschendorff A; Bell C; Morris TJ; Salomoni P; Luong TV; Davidson B; Beck S; Thirlwell C
Endocr Relat Cancer; 2015 Jun; 22(3):L13-8. PubMed ID: 25900181
[No Abstract] [Full Text] [Related]
16. Aberrant Menin expression is an early event in pancreatic neuroendocrine tumorigenesis.
Hackeng WM; Brosens LA; Poruk KE; Noë M; Hosoda W; Poling JS; Rizzo A; Campbell-Thompson M; Atkinson MA; Konukiewitz B; Klöppel G; Heaphy CM; Meeker AK; Wood LD
Hum Pathol; 2016 Oct; 56():93-100. PubMed ID: 27342911
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemically Detected Expression of ATRX, TSC2, and PTEN Predicts Clinical Outcomes in Patients With Grade 1 and 2 Pancreatic Neuroendocrine Tumors.
Uemura J; Okano K; Oshima M; Suto H; Ando Y; Kumamoto K; Kadota K; Ichihara S; Kokudo Y; Maeba T; Nanno Y; Toyama H; Takada Y; Shimada M; Hanazaki K; Masaki T; Suzuki Y
Ann Surg; 2021 Dec; 274(6):e949-e956. PubMed ID: 31599805
[TBL] [Abstract][Full Text] [Related]
18. Clinical features of ATRX or DAXX mutated neuroblastoma.
Kurihara S; Hiyama E; Onitake Y; Yamaoka E; Hiyama K
J Pediatr Surg; 2014 Dec; 49(12):1835-8. PubMed ID: 25487495
[TBL] [Abstract][Full Text] [Related]
19. Alternative Lengthening of Telomeres in Primary Pancreatic Neuroendocrine Tumors Is Associated with Aggressive Clinical Behavior and Poor Survival.
Kim JY; Brosnan-Cashman JA; An S; Kim SJ; Song KB; Kim MS; Kim MJ; Hwang DW; Meeker AK; Yu E; Kim SC; Hruban RH; Heaphy CM; Hong SM
Clin Cancer Res; 2017 Mar; 23(6):1598-1606. PubMed ID: 27663587
[No Abstract] [Full Text] [Related]
20. ATRX loss is an independent predictor of poor survival in pancreatic neuroendocrine tumors.
Chou A; Itchins M; de Reuver PR; Arena J; Clarkson A; Sheen A; Sioson L; Cheung V; Perren A; Nahm C; Mittal A; Samra JS; Pajic M; Gill AJ
Hum Pathol; 2018 Dec; 82():249-257. PubMed ID: 30081149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
